granisetron has been researched along with sirolimus in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bergeron, A; Bergeron, M; Furtado, M; Garofolo, F | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for granisetron and sirolimus
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 other study(ies) available for granisetron and sirolimus
| Article | Year |
|---|---|
Impact of plasma and whole-blood anticoagulant counter ion choice on drug stability and matrix effects during bioanalysis.
Topics: Anticoagulants; Chromatography, Reverse-Phase; Drug Stability; Edetic Acid; Fluconazole; Granisetron; Heparin; Humans; Hydrogen-Ion Concentration; Ions; Limit of Detection; Pharmaceutical Preparations; Sirolimus; Spectrometry, Mass, Electrospray Ionization | 2009 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |